Eyenovia announced that it has enrolled the first patient in the first of two Phase III trials of the company’s MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam. The studies will investigate the safety and efficacy of the company’s first-in-class fixed-combination phenylephrine 2.5%, tropicamide 1% ophthalmic solution, administered as a micro-dose using the Optejet dispenser. Pharmacologic mydriasis is an important part of an estimated 80M office-based comprehensive and diabetic eye exams performed each year in the United States and is essential for the standard dilated retinal fundoscopic examination.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.